Parmax Pharma Ltd — Board Meeting, 14-08-2025: Board Meeting

Parmax Pharma's board approved the financial results for the quarter ending June 30, 2025. The company reported revenue from operations of Rs. 1.94 Cr and a net loss of Rs. 0.76 Cr, impacting the quarter's profitability. Additionally, the board appointed Mr. Samsad Alam Khan as the new Secretarial Auditor for a five-year term, covering FY 2025-26 to FY 2029-30, pending shareholder approval at the upcoming Annual General Meeting. This appointment is a key step to ensure continued regulatory compliance and bolster corporate governance.